therapy

(redirected from antiplatelet therapy)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
See: treatment
References in periodicals archive ?
Consequently, without the clinical evidence I do not think that laboratory testing of antiplatelet therapy has any major role in routine clinical care today, but I will not exclude the possibility of implementing it routinely if future clinical studies would indicate benefit for the patients.
Thus, the duration (and/ or dosing) of antiplatelet therapy may be lowered to minimize the extra bleeding hazard and they should not to be used in combination with OACs until adequate safety data are available.
Before initiating chronic antiplatelet therapy in patients with a history of uker disease, test for and eradicate H.
Early discontinuation of dual antiplatelet therapy (DAPT) has been identified as a major predictor for the occurrence of ST, and for this reason the elderly are at a particularly high-risk for ST due to their expected non-compliance with DAPT," said Dr.
Among the 50 definite thromboses, 34 (68%) occurred a year or more after placement; 15 (44%) occurred while the patients were on dual antiplatelet therapy.
For patients with a high risk of restenosis who cannot tolerate the long-term dual antiplatelet therapy normally associated with DES, it is clear that the Genous Stent is an excellent alternative," added Prof.
These findings are interesting in view of previous studies that showed higher levels of platelet aggregation in insulin-treated diabetes patients after dual antiplatelet therapy compared to diabetes patients not treated with insulin," said Dr.
Groups Urge Extended Dual Antiplatelet Therapy in Drug-Eluting Stent Patients
First Pacific Rim Patients Enrolled into Four-year Public Health Study to Investigate the Duration of Dual Antiplatelet Therapy Following Drug-eluting Stent Procedures
PARIS, May 19, 2011 /PRNewswire/ -- OrbusNeich announced that data from multiple clinical trials supporting the safety and efficacy of the Genous Stent in cases where prolonged dual antiplatelet therapy (DAPT) is not advisable were featured today during the HEALING Symposium titled "How to assess and treat patients who are not suitable candidates for prolonged dual antiplatelet therapy" at EuroPCR 2011 in Paris.
Antiplatelet therapy was stopped five days prior to scheduled surgery in all patients, with an average antiplatelet therapy duration of 12.
The clinical implication of this observation is that current recommendations calling for a few months of dual antiplatelet therapy in drug-eluting stent (DES) recipients need to be revised.